Previous reports ascribe a modulating capacity of the immune response to Helicobacter pylori (HP). Our hypothesis was to demonstrate in a prospective study that HP infection could have a protective effect against development of gastrointestinal GvHD in patients receiving allogeneic hematopoietic cell transplantation (HCT). Presence of HP before transplant was determined using C 13 urea breath test. Seventy-nine patients receiving an allogeneic HCT were included and 93.7% of them received PBSC; in 51.9%, the donor was unrelated. Acute gastrointestinal GvHD was diagnosed in 51.9% (n = 41). In the multivariable analysis, HP infection was associated with a lower frequency of gastrointestinal GvHD (odds ratio (OR) = 0.19 (95% confidence interval (CI): 0.05-0.67); in contrast, an unrelated donor was associated with a higher frequency of gastrointestinal GvHD (odds ratio = 5.4 (95% confidence interval: 1.6-18.2). One year overall survival (OS) was 74%. In the multivariate Cox proportional-hazards regression analysis, stages 0-II gastrointestinal GvHD (hazards ratio (HR) = 0.19), reduced intensity conditioning (HR = 0.04) and tacrolimus-sirolimus GvHD prophylaxis (HR = 0.06) were all associated with a better OS. In summary, HP infection could have a role in decreasing gastrointestinal GvHD in patients receiving allogeneic HCT from peripheral blood including related and unrelated donors.
INTRODUCTION
Allogeneic hematopoietic cell transplant (HCT) is the treatment of choice for many malignant and non-malignant diseases; unfortunately, the risk of mortality is still significant with a transplantrelated mortality ranging between 10 and 50% depending on the patient, donor and disease characteristics; both transplant-related mortality and morbidity are related to the development of GvHD.
1,2 Acute gastrointestinal GvHD is characterized by nausea, anorexia, vomiting, diarrhea, abdominal pain, bleeding and ileus. In its most severe forms GvHD has a mortality risk 480%. 3 Helicobacter pylori (HP) is a gram-negative bacillus that has been related to peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma. HP infection is acquired during childhood and remains present throughout an individual's entire life, although inducing symptoms only appear in a subset of patients. 4, 5 The prevalence of HP infection varies between 20 and 30% in some developed countries and 60 and 80% in other ethnic groups and developing countries. 6 HP does not only colonize the gastric mucosa. The presence of HP has been described in small bowel and colon in addition to many other extraintestinal sites. 7 Chronic HP infection has also been related to several nongastrointestinal diseases. 8, 9 Because of its ability to elicit a chronic immune response in the host, studies have suggested a possible role for HP in the development of autoimmune diseases. 10 HP can produce endoscopic findings similar to those caused by gastrointestinal GvHD (GI-GvHD), and histological analysis may reveal apoptotic bodies. 11, 12 Diagnosis of HP infection is made by either a urea breath test (sensitivity and specificity up to 90%) 13 or mucosal biopsy and histological examination (sensitivity, specificity and positive and negative predictive values of 100, 66, 84 and 100%, respectively). 14 In 2011, we reported a retrospective study analyzing the impact on HP infection on the prevalence of GvHD on 198 patients receiving an allogeneic HCT. The principal finding was that HP infection was associated with a decreased prevalence of intestinal GvHD development. In the retrospective study patients who underwent upper endoscopy for suspected GvHD were included and HP was analyzed on these endoscopies. This represents a significant selection bias. 15 We now report our results from a prospective study of patients whose HP infection state was determined before transplant. The hypothesis to be tested was that pre-HCT HP infection was associated with a lower frequency of GI-GvHD than in HP-non-infected patients.
MATERIALS AND METHODS
This study was approved by the Ethical Clinical Research Committee of the University Hospital of Salamanca, Spain.
Patients selection
This prospective study included consenting adult patients referred to our transplant unit to receive an allotransplant, regardless of indication, from September 2012 to February 2015. Patients less than 18 years old and with proton-pump inhibitors in the last 2 weeks before the performance of a breath test were excluded.
(Otsuka Pharmaceutical Europe Ltd. Wexham, UK). After HCT, all patients with gastrointestinal symptoms consistent with GvHD underwent esophagogastro-duodenoscopy with biopsy. According to our institution guidelines, we performed a gastroscopy for screening of acute gut GvHD, regardless of the upper or lower GvHD symptoms. Colonoscopy is only performed if GvHD is not demonstrated in gastroscopy and/or if symptoms persist as well as if presence of intestinal bleeding or suspicion of viral infection exist. A second HP C13 urea breath test was performed in patients who did not develop symptoms within the first 100 days after HCT. Thus, all the enrolled patients had at least two diagnostic methods to determine HP infection (breath test and/or biopsy) in order to minimize false negative cases.
Clinical variables, endoscopic and histological findings were collected prospectively. Biopsy specimens were sectioned and stained with hematoxylin and eosin. Diagnosis of acute GvHD was established and staged according to the Seattle-Glucksberg modified criteria 16, 17 in stages 0-IV by history, endoscopic appearance and histology, once other possible processes (such as infections or drug toxicity) were ruled out. A HP infection was defined as a positive breath test or HP bacillus was seen in the histological analysis of gastric mucosa. A non-HP case was defined as at least two negative results (breath test and/or biopsy). No HP treatment was indicated before, during or after HCT. The minimum follow-up of patients was 100 days.
The sample size was determined on the basis of our previous retrospective study. The parameters used were: α = 0.05 two sides (significance level of the statistical test), β = 0.20 (corresponding to 80% power) and a rate of patients not will be evaluated at 4%. According to our prior experience collected retrospectively, the incidence of acute GvHD in the presence of HP infection was 15.5%, increasing to 38% in the absence of infection by HP. 
Endoscopic and histological scoring

RESULTS
Descriptive analisys
Out of 120 adult patients who received an allogeneic HTC at our unit in that period, 85 were eligible for this study and 79 were finally included. The reasons of not eligible patients were: Twentytwo patients were receiving proton-pump inhibitor treatment (63%) and they were not willing to stop it. Another seven patients under proton-pump inhibitor treatment were programmed for the transplant in a short period of time (o 2 weeks). Finally, eight patients declined to participate in the study. There were no significantly differences in the incidence of GI-GvHD between the entire group (72.7%; n = 120) and the eligible group (69.6% n = 85).
Baseline characteristics of the study group are summarized in Table 1 . The mean follow-up of patients was 195 days (range: 125-292). Although the overall HP infection rate was 34.2% (n = 27), only three patients had a previous ulcus history and six had received HP therapy. Gastroscopy was performed after HCT in 60 patients (76%) for symptoms consistent with GvHD. The predominant symptoms were anorexia, nausea and vomiting (upper) in 24 patients (40%), diarrhea (lower) in 25 patients (42%) and 11 patients with nausea, vomiting and diarrhea (upper and lower). According to the classification proposed by Cruz-Correa et al., 18 30 patients (49.7%) had endoscopic stages 0 and I, 20 patients (33.3%) stage II and 10 patients stage III (17%). Histological findings were: 29.5% (n = 18) grade 0; 52.5% grade I (n = 32); 8.2% grade II (n = 5); and 9.8% grade III (n = 6). Presence of HP was analyzed in all the endoscopies and rate of HP infection on histological analysis was 31.6% (n = 19). The rate of HP infection obtained in the breath test made on day +100 was 27.7% (n = 5). In the HP-positive pre-HCT group, we detected four false negative in the histological analysis on the biopsies and no one on breath test after HCT. In the negative pre-HCT group we detected one patient with positive HP infection histological analysis and it was interpreted like a pre-HCT false negative breath test. The overall rate of acute GvHD (gastrointestinal, skin or liver) was 69.6% (n = 55). The overall grades of patients with acute GvHD were: 29.1% grade I; grade II in 40%; grade III in 20%; and grade IV 10.9%. There was gastrointestinal involvement in 51.9% (n = 41), skin involvement in 45.6% (n = 36) and liver involvement in 8.9% (n = 7). Regarding GI-GvHD, diagnosis was made at a mean of 35 days post transplantation (range: 6-130). Four patients developed late acute GvHD over 100 days post HCT (+106, +111, +122 and +130). Clinical gastrointestinal GvHD stage was: 27 patients (67.5%) had peak stages I and II and the remaining 32.5% a moderate form (stage III). None of the patients had a stage IV gut GvHD. Regarding GvHD outcome, first-line treatment included: topical treatment with beclomethasone dipropionate and budesonide in 18 patients (44%), systemic treatment with prednisone 1-2 mg/kg in 9 (22%) and both topical and systemic in 14 patients (34%). The rate of response to this first-line therapy was 87.8% (n = 36).
Risk factors for the development of gastrointestinal GvHD: univariate analysis The variables analyzed in the univariate analysis were recipient gender, age, type of donor, HLA mismatching, type of conditioning donor recipient gender mismatch, ABO major incompatibility, GvHD prophylaxis and HP infection ( Table 2 ).
The different proportion of patients with GI-GvHD in the presence of HP infection (10 of 27; 37%) and in the absence of HP infection (31 out of 52; 59.6%) (P = 0.05) was not significant. The proportion of patients with stage GvHD ⩾ stage II was lower in the presence of HP infection (5 out of 27; 18.5%) than in the absence of HP infection (14 out of 52; 26.9%); this difference was not significant (P = 0.4) probably because of the fact that there were more unrelated donors in the HP-positive group. Significant factors related to the frequency of GI-GvHD by univariate analysis included patient female recipient gender (decreased GI-GvHD frequency), unrelated donor (increased GI-GvHD frequency) and myeloablative conditioning (increased GI-GvHD frequency).
We conducted a stratified analysis for the association between HP infection and GI-GvHD in order to detect potential confounders. Unrelated donor was significantly more frequent in HP-positive than in HP negative patients (66% and 34%, respectively) (P = 0.048). HP infection was not associated with the development of acute skin or liver GvHD or with clinical severity or histological grade of GI-GvHD. HP infection was not associated with the location of the symptoms (upper or lower) in acute GI-GvHD.
Risk factors for the development of gastrointestinal GvHD: multivariate analysis In the multivariate model using binary logistic regression to identify factors which might be associated with the development of acute GI-GvHD, we included HP infection, age, recipient gender, type of conditioning, donor type (related/unrelated), donor recipient gender mismatch, ABO major incompatibility and type of GvHD prophylaxis. There was an interaction between the terms HP infection and patient female recipient gender. In a multivariable model, HP infection and patient female recipient gender were independently associated with a lower frequency of GI-GvHD (odds ratio (OR) = 0.19 (95% confidence interval (CI): 0.05-0.67) and OR = 0.2 (95% CI: 0.08-0.87), respectively). An unrelated donor was associated with a higher frequency of GI-GvHD (Table 3) .
Survival analisys
With a median follow-up of 232 days (range: 139-320) for patients alive, five patients (6.3%) have died because of relapse and 15 patients (19%) because of non-relapse mortality; for 73% of them, the cause of death was GvHD-related. HP infection did not impact on overall survival (OS). One year OS is 74%. Regarding variables influencing OS, in the univariate analysis, 1-year survival was higher in related donors (89 vs 56%; P = 0.04), reduced intensity conditioning (77% vs 52%; P = 0.01), no acute GI-GvHD (86% vs 51%; P = 0.04) or stages 0-II GI-GvHD (82% vs 39%; P o 0.001) (Figure 1 ). The variables that obtained statistical significance in the Cox proportional-hazards regression were clinical severity of GI-GvHD (stages 0-II GvHD-associated with a better OS) (hazards ratio = 0.19 (95% CI: 0.06-0.57)), reduced intensity conditioning (hazards ratio = 0.04 (95% CI: 0.006-0.32)) and TacrolimusSirolimus GvHD prophylaxis (hazards ratio = 0.06 (95% CI: 0.01-0.54)).
DISCUSSION
Recent studies suggest that the bacteriological status of the patients receiving allogeneic HCT impacts the risk of developing gastrointestinal GvHD, 20 especially when it concerns the intestinal flora. Multiple studies propose that an appropriate bacteriological status with a good diversity of bacterial colonizing the digestive tract, may cause an immune modulation that protects against development of gastrointestinal GvHD. [21] [22] [23] Although HP is not considered as part of the normal bacterial flora because of its known injurious potential, we know that it has some immunomodulatory capacity. Laboratory tests ascribe a modulating capacity of the immune response to HP, with an increase in the regulatory T cells of the gastric mucosa that might modify the immune response and prevent a Th1/Th17 response. 11, 12 In HP infected human gastric mucosa, an enhanced expression of Indoleamine 2, 3-dioxygenase is capable of modulating Th1/Th2 and Th17 pathways. This mechanism lowers gastric inflammation, possibly contributing to the persistence of HP. 24 Chen and Blaser 25 suggest that the intensity of the response of the host against especially aggressive HP strands (with the cagA gene) might alter the pattern of Th1/Th2 immune response with the subsequent induction of immunoregulating lymphocytes that may prevent immune hyper-reactivity responses, such as asthma or allergy in cases where the Th2 pattern is predominant. It is very well known that intensity of TBI and chemotherapy used during conditioning dictate the integrity of the gastrointestinal mucosa and the subsequent transfer of bacterial lipopolysaccharide and other 'danger/pathogen-associated molecular patterns' (DAMPS/PAMPS) into the systemic circulation. These molecules activate TNF and interleukins 1 and 6 (refs 26-28) and recipient APCs 29 stimulating donor T cells 30, 31 and generating tissue inflammation, allowing the access of T cells to GvHD target tissue. 32 The impact of HP in decreasing acute GvHD could be due to its capacity in promoting an increase of T regulator cells on gastrointestinal tissue; 11, 12, 25 moreover increasing Tregs is associated with a reduced GvHD incidence. 33 Recent meta-analysis suggests that colonization by HP might protect against the development of certain autoimmune disorders, such as asthma 8, 34 and atopic dermatitis. 9 Particularly, Helicobacter pylori infection on acute gastrointestinal GvHD A Velasco-Guardado et al HP neutrophil-activating protein has been shown to act as an immune-modulating agent to suppress Th2 responses in ovalbumin-induced allergic asthma and Trichinella spiralis infection. 35, 36 We should emphasize the negative association that has been established in several studies between inflammatory bowel disease and HP infection with a significant relative risk (RR) lower than 1 in a recent meta-analysis. 37 Thirteen of the studies of this meta-analysis found a RR lower than 1, and in none of them was it higher than 1. The authors concluded that these results suggest that HP infection might have a beneficial effect in the development of inflammatory bowel disease.
Regarding relationship between HP infection and GvHD, two prospective and one retrospective studies have been published till now. Although in the paper by Correia-Silva et al., 38 no relationship between HP infection and the development of GvHD was observed in 46 patients who received an allogeneic transplant, our group reported in a retrospective study 15 with 198 patients that HP infection had a negative modulating effect on the development of acute GvHD (RR = 0.60 (95% CI: 0.46-0.79) P = 0.001) and chronic GvHD (RR = 0.75; (95% CI: 0.61-0.92) P = 0.016). Furthermore, the presence of HP was inversely correlated with the histological severity of GvHD (P = 0.003). Based on that study, we try to demonstrate in a prospective study our hypothesis of the prospective role of HP infection on the appearance of intestinal acute GvHD. In this prospective study with 79 available patients, we again observe that in patients undergoing HCT, HP infection is associated with an independent and statistically significant protective effect against the development of acute GI-GvHD (OR = 0.19 (95% CI: 0.05-0.67)). However, the previous correlation with the histological severity was not confirmed in the present study. One explanation for that is that more patients in the HP-positive group were transplanted from an unrelated donor, which is associated with a higher risk of developing advance grades III and IV GI-GvHD. HP appears as a protective factor of GI-GvHD in the multivariate analysis, which means that this protective factor overcome the type of donor. That could be also the reason of the absence of association between HP infection and a better overall survival; this effect would be subrogated to the development of GI-GvHD.
Another prospective study in 128 patients by Au et al., 39 reported a significant reduction in the risk of developing acute gastrointestinal GvHD (RR = 0.36 (95% CI: 0.13-0.98) P = 0.04) in patients with HP infection. Our data confirm the results of Au et al.; however it is important to point out that Au´s paper includes only patients with sibling donors receiving bone marrow hematopoietic cells; in our study 93% of patients received PBSCs and 51.9% from an unrelated donor; for that reason this scenario is associated with a higher risk of GvHD (18% of gut GvHD in the Au paper as compared with 51% in our series). In our study, female recipient gender had a protective effect on the development of gastrointestinal GI-GvHD. We do not have a causal explanation for this association and it may be related to chance. The important fact is that this association does not appear to operate as a confounding factor on other associations.
To the best of our knowledge, this is the first prospective study suggesting HP infection protection against acute GI-GvHD in non-Asian countries in patients receiving peripheral blood HCT from related and unrelated donors.
Considering the fact that prevalence of HP infection is decreasing in developed countries because of eradication treatments, regular and widespread use of broad-spectrum antibiotics during HCT and that intestinal flora is reduced and changed after chemotherapy, 40 we could observe a slowly progressive increase in the incidence of gastrointestinal GvHD in the future as it has already been observed in some studies. 41 Microbiota injury (because of antibiotics use, oral intake modifications and transplants characteristics), could impact on the GvHD development and our results. However, it should be noted that all the patients included in our study received the same antibiotic and nutrition policy. Nevertheless, new studies considering theses aspects should be performed. Whereas they are available, our recommendation is that before eradicating HP in pre or post-HCT patients, potential protective effect on GvHD should be taken into account. These and other new developments in microbiota will help in the future to decrease intestinal GvHD improving transplant outcome.
